The global diabetes model: user friendly version 3.0

被引：69

作者：

Brown, JB ^{[1
]}

Russell, A ^{[1
]}

Chan, W ^{[1
]}

Pedula, K ^{[1
]}

Aickin, M ^{[1
]}

机构：

[1] Ctr Hlth Res, Portland, OR 97227 USA

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2000年 / 50卷

关键词：

diabetes; computer simulation model; cardiovascular disease; microvascular disease;

D O I：

10.1016/S0168-8227(00)00215-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The attributes of Release 3.0 of the user friendly version (UFV) of the global diabetes model (GDM) are described and documented in detail. The GDM is a continuous, stochastic microsimulation model of type 2 diabetes. Suitable for predicting the medical futures of both individuals with diabetes and representative diabetic populations, the GDM predicts medical events (complications of diabetes), survival, utilities, and medical care costs. Incidence rate functions for microvascular and macrovascular complications are based on a combination of published studies and analyses of data describing diabetic members of Kaiser Permanents Northwest Region, a non-profit group-model health maintenance organization. Active risk factors include average blood glucose (HbAlc), systolic blood pressure (SBP), low density lipoprotein choleslerol (LDL), high density lipoprotein cholesterol (HDL), triglycerides, smoking status, and use of prophylactic aspirin. Events predicted include diabetic eye disease, diabetic nephropathy, peripheral neuropathy, amputation, myocardial infarction, stroke, peripheral artery disease, congestive heart failure, coronary artery surgery, coronary angioplasty, and death. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：S15 / S46

页数：32

共 33 条

[1] THE IMPACT OF DIABETES ON SURVIVAL FOLLOWING MYOCARDIAL-INFARCTION IN MEN VS WOMEN [J].

ABBOTT, RD ;

DONAHUE, RP ;

KANNEL, WB ;

WILSON, PWF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (23) :3456-3460

[2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[3] CARDIOVASCULAR-DISEASE RISK PROFILES [J].

ANDERSON, KM ;

ODELL, PM ;

WILSON, PWF ;

KANNEL, WB .

AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298

[4] EPIDEMIOLOGY OF PERSISTENT PROTEINURIA IN TYPE-II DIABETES-MELLITUS - POPULATION-BASED STUDY IN ROCHESTER, MINNESOTA [J].

BALLARD, DJ ;

HUMPHREY, LL ;

MELTON, LJ ;

FROHNERT, PP ;

CHU, CP ;

OFALLON, WM ;

PALUMBO, PJ .

DIABETES, 1988, 37 (04) :405-412

[5] DIABETIC DYSLIPIDEMIA [J].

BETTERIDGE, DJ .

AMERICAN JOURNAL OF MEDICINE, 1994, 96 :S25-S31

[6] The progressive cost of complications in type 2 diabetes mellitus [J].

Brown, JB ;

Pedula, KL ;

Bakst, AW .

ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (16) :1873-1880

[7] Type 2 diabetes: Incremental medical care costs during the first 8 years after diagnosis [J].

Brown, JB ;

Nichols, GA ;

Glauber, HS ;

Bakst, AW .

DIABETES CARE, 1999, 22 (07) :1116-1124

[8] Primary and subsequent coronary risk appraisal: New results from The Framingham Study [J].

D'Agostino, RB ;

Russell, MW ;

Huse, DM ;

Ellison, RC ;

Silbershatz, H ;

Wilson, PWF ;

Hartz, SC .

AMERICAN HEART JOURNAL, 2000, 139 (02) :272-281

[9] Model of Complications of NIDDM .2. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia [J].

Eastman, RC ;

Javitt, JC ;

Herman, WH ;

Dasbach, EJ ;

CopleyMerriman, C ;

Maier, W ;

Dong, F ;

Manninen, D ;

Zbrozek, AS ;

Kotsanos, J ;

Garfield, SA ;

Harris, M .

DIABETES CARE, 1997, 20 (05) :735-744

[10] Model of complications of NIDDM .1. Model construction and assumptions [J].